General characteristics of the entire study cohort
| Characteristic . | HM (n = 113) . | HM-HLH (n = 112) . | P . | |
|---|---|---|---|---|
| Age at diagnosis, median (25%, 75%), y | 66 (60, 75.5) | 62 (53, 69) | .0002 | |
| Female/male, N (%) | 47 (42)/66 (58) | 48 (43) /64 (57) | .89 | |
| T/NK-cell lymphoma, N (%) | 32 (28) | 26 (23) | .45 | |
| PTCL | 11 (10) | 8 (7) | ||
| Anaplastic large cell lymphoma | 4 (4) | 4 (4) | ||
| CTCL | 3 (3) | 2 (2) | ||
| AITL | 5 (4) | 2 (2) | ||
| GDHSTCL | 2 (2) | 1 (1) | ||
| Nasal/other NK/T-cell lymphoma | 7 (6) | 9 (8) | ||
| B-cell lymphoma, N (%) | 47 (42) | 44 (39) | .89 | |
| DLBCL | 26 (23) | 24 (21) | ||
| IVLBCL | 5 (4) | 7 (6) | ||
| Follicular lymphoma | 6 (5) | 3 (3) | ||
| T-cell/histiocyte-rich large B-cell lymphoma | 1 (1) | 3 (3) | ||
| Other types of B-cell lymphoma | 9 (8) | 7 (6) | ||
| Hodgkin lymphoma, N (%) | 9 (8) | 9 (8) | 1 | |
| AML, N (%) | 7 (6) | 11 (10) | .34 | |
| MDS, N (%) | 8 (7) | 10 (9) | .64 | |
| MPN, N (%) | 6 (5) | 6 (5) | 1 | |
| CLL, N (%) | 4 (3) | 6 (5) | .54 | |
| Eastern | Japan | 62 (55) | 19 (17) | |
| Western | Israel | 23 (20) | 45 (40) | |
| United States | 28 (25) | 48 (43) | ||
| Characteristic . | HM (n = 113) . | HM-HLH (n = 112) . | P . | |
|---|---|---|---|---|
| Age at diagnosis, median (25%, 75%), y | 66 (60, 75.5) | 62 (53, 69) | .0002 | |
| Female/male, N (%) | 47 (42)/66 (58) | 48 (43) /64 (57) | .89 | |
| T/NK-cell lymphoma, N (%) | 32 (28) | 26 (23) | .45 | |
| PTCL | 11 (10) | 8 (7) | ||
| Anaplastic large cell lymphoma | 4 (4) | 4 (4) | ||
| CTCL | 3 (3) | 2 (2) | ||
| AITL | 5 (4) | 2 (2) | ||
| GDHSTCL | 2 (2) | 1 (1) | ||
| Nasal/other NK/T-cell lymphoma | 7 (6) | 9 (8) | ||
| B-cell lymphoma, N (%) | 47 (42) | 44 (39) | .89 | |
| DLBCL | 26 (23) | 24 (21) | ||
| IVLBCL | 5 (4) | 7 (6) | ||
| Follicular lymphoma | 6 (5) | 3 (3) | ||
| T-cell/histiocyte-rich large B-cell lymphoma | 1 (1) | 3 (3) | ||
| Other types of B-cell lymphoma | 9 (8) | 7 (6) | ||
| Hodgkin lymphoma, N (%) | 9 (8) | 9 (8) | 1 | |
| AML, N (%) | 7 (6) | 11 (10) | .34 | |
| MDS, N (%) | 8 (7) | 10 (9) | .64 | |
| MPN, N (%) | 6 (5) | 6 (5) | 1 | |
| CLL, N (%) | 4 (3) | 6 (5) | .54 | |
| Eastern | Japan | 62 (55) | 19 (17) | |
| Western | Israel | 23 (20) | 45 (40) | |
| United States | 28 (25) | 48 (43) | ||
P values were calculated with Fisher’s exact test. AITL, angioimmunoblastic T-cell lymphoma; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CTCL, cutaneous T-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; GDHSTCL, gamma delta hepatosplenic T-cell lymphoma; IVLBCL, intravascular large B-cell lymphoma; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasms; PTCL, peripheral T-cell lymphoma.